Summary
Male Sprague-Dawley rats were given 0.407 mmoles/kg of D,l-α-methyl-p-tyrosine methylester HCl (H44/68; α-MT) at eleven time-points between 0–24h, or 8 doses between 0.013–1.628 mmoles/kg of the drug at 1 h before i. v. injection of 160 μCi tyrosine-2,6-3H. The rats were killed 15 min after tyrosine-3H and brain α-MT, tyrosine and catecholamines (endogenous and labelled), and plasma α-MT and tyrosine (-3H) were chromatographically isolated before being assayed spectrophotofluorimetrically (endogenous) or by liquid scintillation methods (labelled compounds).
A delayed penetration of α-MT from plasma into brain, different elimination rates of α-MT in plasma and brain, and decreasing brain/plasma drug concentration on increasing α-MT dosages indicated, that α-MT in brain and plasma belong to different pharmacokinetic compartments.
The endogenous levels of catecholamines in the time-response experiment, declined to a minimum 4 h after α-MT administration, where the dopamine level was 38% and the noradrenaline level 51% of the saline controls. Kinetic data of the catecholamine elimination is given. In the dose-response experiment the decrease in the endogenous catecholamine levels was doserelated up to 0.407 mmoles/kg of α-MT, with no further decline on higher doses.
The maximal inhibition of brain catecholamine synthesis occurred within 30 min after α-MT administration and the inhibition correlated better with the brain than with plasma α-MT content. The inhibition was dose-related with a maximal synthesis inhibition of 95% for dopamine and 80% for noradrenaline at the highest dose of α-MT. The duration of synthesis inhibition and storage depletion were shorter for noradrenaline (12 h) than for dopamine (16 h). Further, the ED50 for synthesis inhibition of dopamine (0.057 mmoles/kg) was half of the ED50 for synthesis inhibition of noradrenaline (0.117 mmoles/kg). This might suggest different sensitivities towards α-MT or different availabilities of α-MT in the two neuron populations.
At the three highest doses of α-MT there were signs of interference with the uptake process for tyrosine from plasma into the brain. This was indicated by increased plasma levels and decreased brain levels of tyrosine (-3H).
Similar content being viewed by others
References
Andén, N. E., Corrodi, H., Fuxe, K.: Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine- and dopamine-β-hydroxylase inhibitors. J. Pharm. Pharmacol. 24, 177–182 (1972)
Atack, C. V.: The determination of dopamine by a modification of the dihydroxyindole fluorimetric assay. Br. J. Pharmacol. 48, 699–714 (1973)
Barbeau, A.: Biochemistry of Huntington's chorea. In: Advances in Neurology, vol. 1. New York: Raven Press 1973
Besson, M. J., Cherami, A., Glowinski, J.: Effects of some psychotropic drugs on dopamine synthesis in the rat striatum. J. Pharmacol. Exp. Ther. 177, 196–205 (1971)
Beuthin, F. C., Miya, T. S., Blake, D. E., Bousquet, W. F.: Enhanced sensitivity to noradrenergic agonists and tolerance development to α-methyltyrosine in the rat. J. Pharmacol. Exp. Ther. 181, 446–456 (1972)
Brodie, B. B., Costa, E., Dlabac, A., Neff, N. H., Smookler, H. H.: Application of steady state kinetics to the estimation of synthesis rate and turnover time of tissue catecholamines. J. Pharmacol. Exp. Ther. 154, 493–498 (1966)
Brodie, H. K. H., Murphy, D. L., Goodwin, F. K., Bunney, W. E.: Catecholamines and mania: The effect of alpha-methyl-paratyrosine on manic behavior and catecholamine metabolism. Clin. Pharmacol. Ther. 12, 218–224 (1971)
Bunney, B. S., Aghajanian, G. K.: Electrophysiological effects of amphetamine on dopaminergic neurons. In: Frontiers in Catecholamine Research, pp. 957–963. New York: Pergamon Press 1973
Bunney, B. S., Aghajanian, G. K., Roth, R. H.: Comparison of effects of 1-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurons. Nature New Biol. 245, 123–125 (1973a)
Bunney, B. S., Walters, J. R., Roth, R. H., Aghajanian, G. K.: Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity. J. Pharmacol. Exp. Ther. 185, 560–571 (1973b)
Carlsson, A., Lindqvist, M.: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Kbh.) 20, 140–144 (1963)
Carlsson, A., Persson, T., Roos, B.-E., Wålinder, J.: Potentiation of phenothiazines by α-methyltyrosine in treatment of chronic schizophrenia. J. Neural Transm. 33, 83–90 (1972a)
Carlsson, A., Kehr, W., Lindqvist, M., Magnusson, T., Atack, C. V.: Regulation of monoamine metabolism in the central nervous system. Pharmacol. Rev. 24, 371–384 (1972b)
Carr, L. A., Moore, K. E.: Effects of reserpine and α-methyltyrosine on brain catecholamines and the pituitary-adrenal response to stress. Neuroendocrinology 3, 285–302 (1968)
Chang, C. C.: A sensitive method for spectrophotofluorometric assay of catecholamines. Int. J. Neuropharmacol. 3, 643–649 (1964)
Corrodi, H., Hanson, L. C. F.: Central effects of an inhibitor of tyrosine hydroxylation. Psychopharmacologia (Berl.) 10, 116–125 (1966)
Costa, E.: Simple neuronal models to estimate turnover rate of noradrenergic transmitters in vivo. In: Biochemistry of simple neuronal models. Advances in Biochemical Psychopharmacology (E. Costa and E. Giacobini, eds.), Vol. 2. New York: Raven Press 1970
Costa, E., Neff, N. H.: Isotopic and non-isotopic measurements of the rate of catecholamine biosynthesis. In: Biochemistry and pharmacology of the basal ganglia (E. Costa, L. J. Côté, and M. D. Yahr, eds.). New York: Raven Press 1966
Dixon, W. J., Massey, F. J., Jr.: Introduction to statistical analysis. New York: McGraw-Hill Book Company 1969
Dominic, J. A., Moore, K. E.: Acute effects of α-methyltyrosine on brain catecholamine levels and on spontaneous and amphetamine-stimulated motor activity in mice. Arch. Int. Pharmacodyn. 178, 166–176 (1969)
Dost, F. H.: Grundlagen der Pharmakokinetik. Stuttgart: G. Thieme 1968
Doteuchi, M., Wang, C., Costa, E.: Compartmentation of dopamine in rat striatum. Mol. Pharmacol. 10, 225–234 (1974)
Engelman, K., Jéquier, E., Udenfriend, S., Sjoerdsma, A.: Metabolism of α-methyltyrosine in man: Relationship to its potency as an inhibitor of catecholamine biosynthesis. J. Clin. Invest. 47, 568–576 (1968)
Fernstrom, J. D.: The effect of nutritional factors on brain amino acid levels and monoamine synthesis. Fed. Proc. 35, 1151–1156 (1976)
Groves, P. M., Wilson, C. J., Young, S. J., Rebec, G. V.: Selfinhibition by dopaminergic neurons. Science 190, 522–529 (1975)
Groves, P. M., Young, S. J., Wilson, C. J.: Self-inhibition by dopaminergic neurones: Disruption by (±)-α-methyl-p-tyrosine pretreatment or anterior diencephalic lesions. Neuropharmacology 15, 755–762 (1976)
Hanson, L. C. F.: The disruption of conditioned avoidance response following selective depletion of brain catecholamines. Psychopharmacologia (Berl.) 8, 100–110 (1965)
Hanson, L. C. F.: Biochemical and behavioural effects of tyrosine hydroxylase inhibition. Psychopharmacologia (Berl.) 11, 8–17 (1967)
Javoy, F., Glowinski, J.: Dynamic characteristics of the “functional compartment” of dopamine in dopaminergic terminals of the rat striatum. J. Neurochem. 18, 1305–1311 (1971)
Jönsson, L.-E., Änggård, E., Gunne, L.-M.: Blockade of intravenous amphetamine euphoria in man. Clin. Pharmacol. Ther. 12, 889–896 (1971)
Koyuncuoğlu, H., Eroğlu, L., Güngör, M.: The effects of dl-p-chlorophenylalanine and dl-α-methyl-p-tyrosine on the brain catecholamine, serotonin and free amino acid contents in rat. Psychopharmacologia (Berl.) 45, 163–166 (1975)
Lewander, T., Jonsson, J.: Isolation and determination of free endogenous and radioactive tyrosine in studies on catecholamine synthesis in rat brain. Life Sci. 7, 386–393 (1968)
Levitt, M., Spector, S., Udenfriend, S.: Formation of norepinephrine by the isolated heart. Fed. Proc. 23, 562 (1964)
Levitt, M., Gibb, J. W., Daly, J. W., Lipton, M., Udenfriend, S.: A new class of tyrosine hydroxylase inhibitors and a simple assay of inhibition in vivo. Biochem. Pharmacol. 16, 1313–1321 (1967)
McGeer, P. L., Bagchi, S. P., McGeer, E. G.: Subcellular localization of tyrosine hydroxylase in beef caudate nucleus. Life Sci. 4, 1859–1867 (1965)
Moore, K. E.: Effects of α-methyltyrosine on brain catecholamines and conditioned behavior in guinea pigs. Life Sci. 5, 55–65 (1966)
Moore, K. E., Dominic, J. A.: Tyrosine hydroxylase inhibitors. Fed. Proc. 30, 859–870 (1971)
Nagatsu, T., Levitt, M., Udenfriend, S.: Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J. Biol. Chem. 239, 2910–2917 (1964)
Nybäck, H.: Effects of neuroleptic drugs on brain catecholamine neurons. An experimental study using 14C-labelled tyrosine. Stockholm: Kihlström & Söner Boktryckeri AB 1971a
Nybäck, H.: Regional disappearance of catecholamines formed from 14C-tyrosine in rat brain: Effect of synthesis inhibitors and of chlorpromazine. Acta Pharmacol. Toxicol. 30, 372–384 (1971b)
Nybäck, H., Sedvall, G.: Effect of chlorpromazine on accumulation and disappearance of catecholamines formed from tyrosine-C14 in brain. J. Pharmacol. Exp. Ther. 162, 294–301 (1968)
Paden, C.: A revised method for studying the kinetic compartmentation of dopamine in rat striatum. Neuroscience Abstr. 2, 793 (1976)
Papeschi, R., Randrup, A.: Catalepsy, sedation and hypothermia induced by alpha-methyl-p-tyrosine in the rat. An ideal tool for screening of drugs active on central catecholaminergic receptors. Pharmacopsychiat. 6, 137–157 (1973)
Persson, T., Waldeck, B.: Some problems encountered in attempting to estimate catecholamine turnover using labelled tyrosine. J. Pharm. Pharmacol. 22, 473–478 (1970)
Rech, R. H., Borys, H. K., Moore, K. E.: Alteractions in behavior and brain catecholamine levels in rats treated with α-methyltyrosine. J. Pharmacol. Exp. Ther. 153, 412–419 (1966)
Reis, D. J., Ross, R. A., Pickel, V. M., Lewander, T., Joh, T. H.: Some differences in tyrosine hydroxylase in central noradrenergic and dopaminergic neurons. In: Chemical tools in catecholamine research, vol. II, (O. Almgren, A. Carlsson and J. Engel, eds.). Amsterdam: North-Holland Publishing Company 1975
Scheel-Krüger, J.: Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain. Eur. J. Pharmacol. 14, 47–59 (1971)
Schoenfeld, R. I., Seiden, L. S.: Effect of α-methyltyrosine on operant behavior and brain catecholamine levels. J. Pharmacol. Exp. Ther. 167, 319–327 (1969)
Spector, S., Inhibitors of endogenous catecholamine biosynthesis. Pharmacol. Rev. 18, 599–609 (1966)
Spector, S., Sjoerdsma, A., Udenfriend, S.: Blockade of endogenous norepinephrine synthesis by α-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. J. Pharmacol. Exp. Ther. 147, 86–95 (1965)
Stein, D., Jouvet, M., Pujol, J.-F.: Effects of α-methyl-p-tyrosine upon amine metabolism and sleep states in the cat. Brain Res. 72, 360–365 (1974)
Stern, W. C., Morgane, P. J.: Effects of α-methyltyrosine on REM sleep and brain amine levels in the cat. Biol. Psychiatry 6, 301–305 (1973)
Stolk, J. M., Rech, R. H.: Antagonism of D-amphetamine by alphamethyl-L-tyrosine: Behavioral evidence for the participation of catecholamine stores and synthesis in the amphetamine stimulant response. Neuropharmacology 9, 249–263 (1970)
Sulser, F., Owens, M. L., Norvich, M. R., Dingell, J. V.: The relative role of storage and synthesis of brain norepinephrine in the psychomotor stimulation evoked by amphetamine or by desipramine and tetrabenazine. Psychopharmacologia (Berl.) 12, 322–332 (1968)
Svensson, T. H., Waldeck, B.: On the role of brain catecholamines in motor activity: Experiments with inhibitors of synthesis and of monoamine oxidase. Psychopharmacologia (Berl.) 18, 357–365 (1970)
Svensson, T. H., Waldeck, B.: On the relation between motor activity and the degree of enzyme inhibition following inhibition of tyrosine hydroxylase. Acta Pharmacol. Toxicol. (Kbh.) 29, 60–64 (1971)
Takahashi, S., Gjessing, L. R.: A fluorometric method combined with thin layer chromatography for determination of norepinephrine, epinephrine and dopamine in human urine. Clin. Chim. Acta 36, 369–378 (1972)
Udenfriend, S., Zaltzman-Nirenberg, P., Nagatsu, T.: Inhibitors of purified beef adrenal tyrosine hydroxylase. Biochem. Pharmacol. 14, 837–845 (1965)
Waalkes, T. P., Udenfriend, S.: A fluorometric method for the estimation of tyrosine in plasma and tissues. J. Lab. Clin. Med. 50, 733–736 (1957)
Weiner, N.: A critical assessment of methods for the determination of monoamine synthesis turnover rates in vivo. In: Neuropsychopharmacology of monoamines and their regulatory enzymes (E. Usdin, ed.). New York: Raven Press 1974
Weissman, A., Koe, B. K.: Behavioral effects of L-α-methyltyrosine, an inhibitor of tyrosine hydroxylase. Life Sci. 4, 1037–1048 (1965)
Widerlöv, E., Lewander, T.: The relationship between amphetamine antagonism and depletion of brain catecholamines by alphamethyl-p-tyrosine in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 304, 125–134 (1978)
Wurtman, R. J., Larin, F., Mostafapour, S., Fernstrom, J. D.: Brain catechol synthesis: Control by brain tyrosine concentration. Science 185, 183–184 (1974)
Wurtman, R. J., Fernstrom, J. D.: Control of brain neurotransmitter synthesis by precursor availability and nutritional state. Biochem. Pharmacol. 25, 1691–1696 (1976)
Wålinder, J., Skott, A., Carlsson, A., Roos, B.-E.: Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind cross-over technique. Arch. Gen. Psychiatry 33, 501–505 (1976)
Änggård, E., Gunne, L.-M.: Clinical and pharmacological studies of amphetamine-dependent subjects. Neuropsychopharmacology. Proceedings of the IX Congress of the Collegium Internationale Neuropsychopharmacologicum, Paris 7–12 July (1974), pp. 253–261. Excerpta Medica International Congress Series No. 359, Amsterdam 1975
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Widerlöv, E., Lewander, T. Inhibition of the in vivo biosynthesis and changes of catecholamine levels in rat brain after α-methyl-p-tyrosine; time- and dose-response relationships. Naunyn-Schmiedeberg's Arch. Pharmacol. 304, 111–123 (1978). https://doi.org/10.1007/BF00495547
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00495547